Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients

키워드

참고문헌 (103)

1. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
2. Ripperger T, "Breast cancer susceptibility : current knowledge and implications for genetic counselling", Eur J Hum Genet, 17, pp.722~731 (2009)
3. Fackenthal JD, "Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations", Nat Rev Cancer, 7, pp.937~948 (2007)
4. Ford D, "Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium", Am J Hum Genet, 62, pp.676~689 (1998)
5. Antoniou A, "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history : a combined analysis of 22 studies", Am J Hum Genet, 72, pp.1117~1130 (2003)
6. Chen S, "Meta-analysis of BRCA1 and BRCA2 penetrance", J Clin Oncol, 25, pp.1329~1333 (2007)
7. Ferla R, "Founder mutations in BRCA1 and BRCA2 genes", Ann Oncol, 18(Suppl 6), pp.vi93~vi98 (2007)
8. Daly MB, "Genetic", familial high-risk assessment : breast and ovarian, 2010, pp.8, 562~594
9. Gonzalez-Angulo AM, "Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer", Clin Cancer Res, 17, pp.1082~1089 (2011)
10. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
11. Shin HR, "Cancer control in the Asia Pacific region : current status and concerns", Jpn J Clin Oncol, 42, pp.867~881 (2012)
12. 고범석, "Changing Patterns in the Clinical Characteristics of Korean Breast Cancer from 1996-2010 Using an Online Nationwide Breast Cancer Database", Journal of Breast Cancer, 15(4), pp.393~400 (2012), 한국유방암학회[DOI]
13. 김해영, "Distributions of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer", Journal of Breast Cancer, 16(4), pp.357~365 (2013), 한국유방암학회
14. Yang L, "Estimates of cancer incidence in China for 2000 and projections for 2005", Cancer Epidemiol Biomarkers Prev, 14, pp.243~250 (2005)
15. Kurian AW, "Lifetime risks of specific breast cancer subtypes among women in four racial", ethnic groups, 2010, pp.12, R99~
16. Anglian Breast Cancer Study Group, "Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group", Br J Cancer, 83, pp.1301~1308 (2000)
17. Lang GT, "The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China : screening of 2, 991 patients and 1, 043 controls by next-generation sequencing", Int J Cancer, 141, pp.129~142 (2017)
18. Ford D, "Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium", Lancet, 343, pp.692~695 (1994)
19. Easton DF, "Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium", Am J Hum Genet, 56, pp.265~271 (1995)
20. Struewing JP, "The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews", N Engl J Med, 336, pp.1401~1408 (1997)
21. 한상아, "BRCA1 및BRCA2 유전자 돌연변이에 기인한 한국인 유방암 및 난소암 위험도: 예비 연구 결과보고", Journal of Breast Cancer, 12(2), pp.92~99 (2009), 한국유방암학회
22. Ikeda N, "Frequency of BRCA1 and BRCA2 germline mutations detected by protein truncation test and cumulative risks of breast and ovarian cancer among mutation carriers in Japanese breast cancer families", J Korean Breast Cancer Soc, 5, pp.194~201 (2002)
23. Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
24. Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
25. Han SA, "The prevalence of BRCA mutations among familial breast cancer patients in Korea : results of the Korean Hereditary Breast Cancer study", Fam Cancer, 12, pp.75~81 (2013)
26. Sugano K, "Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast", ovarian cancer, 2008, pp.99, 1967~1976
27. Kwong A, "Identification of BRCA1", 2founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis, 2012, pp.7, e43994~
28. Valarmathi MT, "Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families", Hum Mutat, 23, pp.205~ (2004)
29. Kwong A, "Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer", Hugo J, 3, pp.63~76 (2009)
30. Yip CH, "Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country", World J Surg, 33, pp.2077~2081 (2009)
31. Wooster R, "Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13", Science, 265, pp.2088~2090 (1994)
32. Breast Cancer Linkage Consortium, "Cancer risks in BRCA2 mutation carriers", J Natl Cancer Inst, 91, pp.1310~1316 (1999)
33. Thompson D, "Cancer incidence in BRCA1 mutation carriers", J Natl Cancer Inst, 94, pp.1358~1365 (2002)
34. FitzGerald MG, "Germ-line BRCA1 mutations in Jewish and non-Jewish women with earlyonset breast cancer", N Engl J Med, 334, pp.143~149 (1996)
35. Shattuck-Eidens D, "BRCA1 sequence analysis in women at high risk for susceptibility mutations : risk factor analysis and implications for genetic testing", JAMA, 278, pp.1242~1250 (1997)
36. Malone KE, "BRCA1 mutations and breast cancer in the general population : analyses in women before age 35 years and in women before age 45 years with first-degree family history", JAMA, 279, pp.922~929 (1998)
37. Hodgson SV, "Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer", J Med Genet, 36, pp.369~373 (1999)
38. Warner E, "Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer", J Natl Cancer Inst, 91, pp.1241~1247 (1999)
39. Langston AA, "BRCA1 mutations in a population-based sample of young women with breast cancer", N Engl J Med, 334, pp.137~142 (1996)
40. Peto J, "Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer", J Natl Cancer Inst, 91, pp.943~949 (1999)
41. Ligtenberg MJ, "Characteristics of small breast and", or ovarian cancer families with germline mutations in BRCA1 and BRCA2, 1999, pp.79, 1475~1478
42. Krainer M, "Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer", N Engl J Med, 336, pp.1416~1421 (1997)
43. Hartge P, "The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews", Am J Hum Genet, 64, pp.963~970 (1999)
44. Hopper JL, "Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2", Am J Hum Genet, 65, pp.1771~1776 (1999)
45. Foulkes WD, "The importance of a family history of breast cancer in predicting the presence of a BRCA mutation", Am J Hum Genet, 65, pp.1776~1779 (1999)
46. Li WF, "The prevalence of BRCA1 and BRCA2germline mutations in high-risk breast cancer patients of Chinese Han nationality : two recurrent mutations were identified", Breast Cancer Res Treat, 110, pp.99~109 (2008)
47. Zhang J, "Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer", Breast Cancer Res Treat, 132, pp.421~428 (2012)
48. De Leon Matsuda ML, "BRCA1 and BRCA2mutations among breast cancer patients from the Philippines", Int J Cancer, 98, pp.596~603 (2002)
49. Marcus JN, "Hereditary breast cancer : pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage", Cancer, 77, pp.697~709 (1996)
50. Johannsson OT, "Survival of BRCA1breast and ovarian cancer patients : a population-based study from southern Sweden", J Clin Oncol, 16, pp.397~404 (1998)
51. Robson M, "BRCA-associated breast cancer in young women", J Clin Oncol, 16, pp.1642~1649 (1998)
52. Noguchi S, "Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women", Cancer, 85, pp.2200~2205 (1999)
53. Couch FJ, "BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer", N Engl J Med, 336, pp.1409~1415 (1997)
54. Verhoog LC, "Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1", Lancet, 351, pp.316~321 (1998)
55. Johannsson OT, "Tumour biological features of BRCA1-induced breast and ovarian cancer", Eur J Cancer, 33, pp.362~371 (1997)
56. Armes JE, "The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations : a populationbased study", Cancer, 83, pp.2335~2345 (1998)
57. Garcia-Patiño E, "Germ-line BRCA1 mutations in women with sporadic breast cancer : clinical correlations", J Clin Oncol, 16, pp.115~120 (1998)
58. 유종한, "Characteristics of BRCA1", 2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry, 2014, pp.17(2), 129~135[DOI]
59. Foulkes WD, "Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer", Clin Cancer Res, 3(12 Pt 1), pp.2465~2469 (1997)
60. Verhoog LC, "Survival in hereditary breast cancer associated with germline mutations of BRCA2", J Clin Oncol, 17, pp.3396~3402 (1999)
61. Wagner TM, "BRCA1-related breast cancer in Austrian breast and ovarian cancer families : specific BRCA1 mutations and pathological characteristics", Int J Cancer, 77, pp.354~360 (1998)
62. Eisinger F, "Low frequency of lymph-node metastasis in BRCA1-associated breast cancer", Lancet, 351, pp.1633~1634 (1998)
63. Stoppa-Lyonnet D, "Familial invasive breast cancers : worse outcome related to BRCA1 mutations", J Clin Oncol, 18, pp.4053~4059 (2000)
64. Robson ME, "A combined analysis of outcome following breast cancer : differences in survival based on BRCA1", BRCA2 mutation status and administration of adjuvant treatment, 2004, pp.6, R8~17
65. Ansquer Y, "Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group", Lancet, 352, pp.541~ (1998)
66. Moran MS, "Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer", Cancer, 113, pp.2565~2574 (2008)
67. Foulkes WD, "Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome", Ann Oncol, 11, pp.307~313 (2000)
68. Nilsson MP, "Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1", 2 mutation status, 2014, pp.144, 133~142
69. Nicoletto MO, "BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling", Cancer Treat Rev, 27, pp.295~304 (2001)
70. El-Tamer M, "Survival and recurrence after breast cancer in BRCA1", 2 mutation carriers, 2004, pp.11, 157~164
71. Albano WA, "Natural history of hereditary cancer of the breast and colon", Cancer, 50, pp.360~363 (1982)
72. Porter DE, "Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21", Br J Surg, 81, pp.1512~1515 (1994)
73. Rennert G, "Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations", N Engl J Med, 357, pp.115~123 (2007)
74. Bordeleau L, "Prognosis of BRCA-associated breast cancer : a summary of evidence", Breast Cancer Res Treat, 119, pp.13~24 (2010)
75. Lee EH, "Effect of BRCA1", 2 mutation on short-term and long-term breast cancer survival : a systematic review and meta-analysis, 2010, pp.122, 11~25
76. Xu J, "Clinical implications for BRCA gene mutation in breast cancer", Mol Biol Rep, 39, pp.3097~3102 (2012)
77. Lucassen A, "Evidence based case report : advice about mammography for a young woman with a family history of breast cancer", BMJ, 322, pp.1040~1042 (2001)
78. Chappuis PO, "Clinico-pathological characteristics of BRCA1-and BRCA2-related breast cancer", Semin Surg Oncol, 18, pp.287~295 (2000)
79. Seynaeve C, "Ipsilateral breast tumour recurrence in hereditary breast cancer following breastconserving therapy", Eur J Cancer, 40, pp.1150~1158 (2004)
80. Haffty BG, "Outcome of conservatively managed early-onset breast cancer by BRCA1", 2 status, 2002, pp.359, 1471~1477
81. "Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium", Lancet, 349, pp.1505~1510 (1997)
82. Eisinger F, "Mutations at BRCA1 : the medullary breast carcinoma revisited", Cancer Res, 58, pp.1588~1592 (1998)
83. Lakhani SR, "Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations", J Natl Cancer Inst, 90, pp.1138~1145 (1998)
84. Honrado E, "The molecular pathology of hereditary breast cancer : genetic testing and therapeutic implications", Mod Pathol, 18, pp.1305~1320 (2005)
85. Lynch BJ, "Pathobiologic characteristics of hereditary breast cancer", Hum Pathol, 29, pp.1140~1144 (1998)
86. Eerola H, "Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families", Breast Cancer Res, 7, pp.R93~100 (2005)
87. Agnarsson BA, "Inherited BRCA2 mutation associated with high grade breast cancer", Breast Cancer Res Treat, 47, pp.121~127 (1998)
88. Lakhani SR, "The pathology of familial breast cancer : predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2", J Clin Oncol, 20, pp.2310~2318 (2002)
89. Palacios J, "Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations : differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers", Clin Cancer Res, 9(10 Pt 1), pp.3606~3614 (2003)
90. Foulkes WD, "Estrogen receptor status in BRCA1-and BRCA2-related breast cancer : the influence of age, grade, and histological type", Clin Cancer Res, 10, pp.2029~2034 (2004)
91. Osin PP, "The pathology of familial breast cancer : immunohistochemistry and molecular analysis", Breast Cancer Res, 1, pp.36~40 (1999)
92. Eisinger F, "More about : multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations", J Natl Cancer Inst, 91, pp.1421~1422 (1999)
93. Armes JE, "Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers : a population-based study", Cancer Res, 59, pp.2011~2017 (1999)
94. Grushko TA, "Molecular-cytogenetic analysis of HER-2", neu gene in BRCA1-associated breast cancers, 2002, pp.62, 1481~1488
95. Foulkes WD, "Triple-negative breast cancer", N Engl J Med, 363, pp.1938~1948 (2010)
96. Mavaddat N, "Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers : results from the Consortium of Investigators of Modifiers of BRCA1", 2(CIMBA), 2012, pp.21, 134~147
97. Atchley DP, "Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer", J Clin Oncol, 26, pp.4282~4288 (2008)
98. Sharma P, "Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry : implications for hereditary breast and", or ovarian cancer syndrome testing, 2014, pp.145, 707~714
99. 노재명, "Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation", Journal of Breast Cancer, 16(3), pp.308~314 (2013), 한국유방암학회
100. Claus EB, "Prevalence of BRCA1and BRCA2 mutations in women diagnosed with ductal carcinoma in situ", JAMA, 293, pp.964~969 (2005)
101. Hoogerbrugge N, "High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer", J Clin Oncol, 21, pp.41~45 (2003)
102. Kauff ND, "Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations", Cancer, 97, pp.1601~1608 (2003)
103. Adem C, "Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers", Cancer, 97, pp.1~11 (2003)

관련 논문AI추천